The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Fize Medical; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Noel Clarke
Honoraria - AstraZeneca; Bayer; Janssen; Pfizer
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Epic Sciences; Exelixis; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; ZAlpha
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Janssen; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma
 
Giuseppe Procopio
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (BMS); Eisai; Ipsen; Janssen; Merck Sharp & Dohme; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Astellas Pharma; Ipsen; Janssen Oncology
 
João Daniel Cardoso Guedes
Honoraria - Agenus; AstraZeneca/Merck; Daiichi Sankyo; Merck; Pierre Fabre; Pint Pharma
Research Funding - Agenus; Amgen; ARO-Einstein; AstraZeneca; Bayer; Blau Farmaceutica; Boehringer Ingelheim; BRAVA Foundation; Bristol Myers Squibb Foundation; Daiichi Sankyo; Eurofarma; Genentech; HUYA Bioscience International; Incyte; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Polyphor; PTC Therapeutics; Roche; Sanofi; Seagen; Takeda
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences
 
Cagatay Arslan
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst); Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/Merck (Inst); Bristol Myers Squibb Foundation (Inst); Janssen-Cilag (Inst)
 
Emma Brown
Research Funding - AstraZeneca; Merck
 
Friederike Schlürmann
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Janssen; Lilly; Merck Sharp & Dohme
Expert Testimony - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Janssen; Lilly; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Janssen
 
Jae Young Joung
Honoraria - Astellas Pharma; Johnson & Johnson/Janssen; Sanofi/Aventis
 
Mikio Sugimoto
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kissei Pharmaceutical; Nippon Shinyaku; Novartis; Pfizer; Takeda
 
Karina Vianna
Consulting or Advisory Role - Adium Pharma; AstraZeneca; Roche/Genentech
Speakers' Bureau - AstraZeneca; Bayer; BMS Brazil; GlaxoSmithKline; Knight Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb Brazil (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
Christian Hosius
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Alan Barnicle
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - patent pending for early stage project with current employer
Travel, Accommodations, Expenses - AstraZeneca
 
Yu-Zhen Liu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Elizabeth Harrington
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
David McGuinness
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Paula Michelle del Rosario
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)